New Imaging
Positron Emission Tomography (PET) is a non-invasive medical imaging technique which allows the bio-distribution and pharmacokinetics of labelled molecules to be visualised in vivo. The global market for PET technologies and reagents has demonstrated significant growth over the last 5 years, with 1.8 million clinical procedures valued at $332 million being conducted in 2007, a 21% increase on 2006. This rapid growth is expected to continue as access to PET services increases with 7.1 million annual clinical procedures predicted globally by 2015 ($1,324M). Currently, the vast majority of this market involves the application of a single imaging tracer; [18F]FDG, in a single diagnostic area i.e. oncology.
With the strategic vision of meeting the increasing demands of this market-place, NewImaging Ltd has developed the first generic, efficient and highly selective methodology for the formation of [18F]fluoroarenes – the key functionality of choice for PET imaging agents. This proprietary methodology places little or no restriction on the original base substrate, permitting the synthesis of agents previously unavailable via traditional methods and facilitating both translation and early adoption onto the various automated platforms already in routine clinical, academic, and industrial use.
NewImaging Ltd is therefore uniquely placed to take advantage of the continuing global expansion in PET imaging services and lead on the development of novel second generation imaging agents that can be applied across multiple therapeutic areas.
Contact:
Dr Michael Carroll
School of Chemistry
Newcastle University
Newcastle upon Tyne
NE1 7RU
t: +44(0)191 2227074
f: +44(0)191 2226929
e: m.a.carroll@ncl.ac.uk